相关实验视频
Updated: Jan 17, 2026

02:26
Intracranial Pharmacotherapy and Pain Assays in Rodents
Published on: April 9, 2019
5.8K
药物基因组学在优化胺治疗对截肢后疼痛的作用
Alix Tappe1, Emily Burzynski1, Jhanvi Patel1
1Anesthesiology and Intensive Care Scientific Circle English Division (ANKONA ED), Medical University of Warsaw, 02-091 Warsaw, Poland.
Reports (MDPI)
|September 22, 2025
概括
氨酸对治疗截肢后疼痛 (PAP) 有希望,包括幻肢疼痛 (PLP) 和残余肢痛 (RLP). 遗传因素影响胺胺.
科学领域:
- 药理学 药理学是指药理学的学科.
- 疼痛管理 疼痛管理
- 遗传学 遗传学 是一个
背景情况:
- 截肢后疼痛 (PAP),包括残余四肢疼痛 (RLP) 和幻肢疼痛 (PLP),显著影响患者的康复和生活质量.
- 胺,一种NMDA受体对抗剂,正在研究其在治疗耐火性PAP的有效性.
研究的目的:
- 审查凯胺对PAP的疗效.
- 探索药物基因组学在优化PAP胺治疗中的作用.
主要方法:
- 对主要数据库 (PubMed,Embase,Cochrane) 进行了全面的文献审查.
- 该审查侧重于临床试验,系统性审查和研究,调查基因对胺代谢和患者反应的影响.
主要成果:
- 在外科手术期间服用胺可以减少PAP的严重程度和阿片类药物消费.
- 患者对胺的反应各不相同,有些人经历了短期的缓解,而另一些人则长期受益.
- 在CYP2B6,CYP3A4/5,COMT Val158Met,SLC6A2和KCNS1中的遗传变异影响了胺代谢,疗效和副作用概况.
结论:
- 不一致的胺剂量协议和有限的基因数据使用阻碍了标准化治疗.
- 进一步研究基因型导向的胺蛋白协议对于改善治疗结果和在截肢护理中实现精确止痛至关重要.
相关概念视频
Parenteral Anesthetics: Overview
610
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
610
Nonlinear Pharmacokinetics: Overview
1.1K
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
1.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
257
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
257
Dosage Regimens: Partial Pharmacokinetic Parameters
155
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
155
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
215
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
215

